APELOA(000739)2025-03-10 14:10Financial Performance - The company's operating revenue for 2024 reached ¥12,021,863,029.21, an increase of 4.77% compared to ¥11,474,162,365.59 in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥1,031,121,698.55, a decrease of 2.29% from ¥1,055,340,740.79 in 2023[22]. - The net profit after deducting non-recurring gains and losses was ¥984,439,126.95, down 4.09% from ¥1,026,437,851.58 in 2023[22]. - The cash flow from operating activities increased by 17.20% to ¥1,208,753,683.01 from ¥1,031,363,074.08 in 2023[22]. - Basic earnings per share for 2024 were ¥0.8864, a decrease of 1.78% from ¥0.9025 in 2023[22]. - The total assets at the end of 2024 were ¥12,729,008,610.16, a slight decrease of 0.30% from ¥12,767,664,072.34 at the end of 2023[22]. - The net assets attributable to shareholders increased by 8.34% to ¥6,741,964,785.16 from ¥6,222,728,875.43 at the end of 2023[22]. - The company reported a quarterly revenue of ¥3,198,046,619.86 in Q1 2024, with a net profit of ¥243,716,289.99 attributable to shareholders[26]. - The weighted average return on equity for 2024 was 16.09%, down from 18.17% in 2023[22]. - The gross profit margin for the pharmaceutical main business was 23.84%, a decrease of 1.76% from the previous year[74]. Research and Development - Research and development expenses for the company reached ¥64,147.18 million in 2024, representing a year-on-year increase of 2.66% and accounting for 5.34% of total revenue[39]. - The company has a total of 1,156 R&D personnel, including 54 PhDs and 405 Master's degree holders[39]. - The company is focusing on innovation and has established multiple technology centers across its business segments to enhance R&D capabilities[39]. - The company has strengthened its project application and patent acquisition processes, although specific numbers were not disclosed in the report[40]. - The company has submitted 409 patent applications, with 145 valid patents, including 134 inventions and 11 utility models[41]. - The company has established eight major technology platforms to support its API and CDMO businesses, enhancing its competitive edge in the market[56]. Market and Industry Outlook - The global pharmaceutical market is projected to reach $2.5 trillion by 2030, driven by an aging population and increasing healthcare demands[33]. - The Chinese pharmaceutical market is expected to grow to ¥2.89 trillion by 2030, capturing approximately 1/6 of the global market share[34]. - The company is actively involved in the production and sales of various pharmaceutical products, including APIs and innovative drug development services[38]. - The company is advancing its "2030 development strategy," focusing on refining raw materials, strengthening CDMO, and expanding into medical aesthetics[66]. Environmental Compliance - The company has established a comprehensive EHS management system, with 11 wastewater treatment systems capable of processing 5.4 million tons of wastewater annually[48]. - The company has implemented a "three simultaneous" system for new projects, ensuring environmental impact assessments are conducted alongside construction[154]. - The company is committed to enhancing its environmental monitoring capabilities as per national guidelines[153]. - The company is focusing on compliance with the latest environmental regulations, including the 2024 version of the Industrial Structure Adjustment Guidance Catalog[152]. - The company has achieved a reduction in various pollutants, with emissions from waste gas treatment facilities consistently below national and local standards[169]. Corporate Governance - The company operates under a "business unit + functional" management structure, which includes four business units and various functional departments[111]. - The company emphasizes independence from its controlling shareholders in terms of assets, personnel, and financial operations[113]. - The company has implemented internal control measures in accordance with its internal control implementation guidelines[112]. - The company has established a performance-based salary system for senior management, linking remuneration to both company and individual performance[126]. - The company has not reported any significant discrepancies in its governance practices compared to regulatory requirements[112]. Shareholder Returns - The company plans to distribute a cash dividend of ¥3.56 per 10 shares, totaling approximately ¥413,000,000 based on the adjusted share capital[5]. - The company reported a cash dividend of 412,405,913.06 CNY, with a total cash dividend including other methods amounting to 612,608,349.59 CNY, representing 100% of the total profit distribution[140]. - The company has a profit distribution policy that mandates a minimum cash dividend ratio of 40% during profit distribution when in a mature development stage with significant capital expenditure plans[140]. Strategic Initiatives - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[116]. - The company is currently in the process of submitting domestic and international application materials for several products, indicating ongoing expansion efforts[85]. - The company is committed to enhancing its production capabilities while managing associated uncertainties in the development process[83]. - The company is pursuing multiple avenues for product line expansion, with several projects currently under review for market approval[84]. Employee and Talent Management - The company has recruited 21 key talents, including 11 PhDs, and hired 568 recent graduates in relevant fields to support innovation and capacity expansion[49]. - The company conducted a training needs survey in October, with an annual training plan developed by December based on strategic development needs[138]. - The total number of employees at the end of the reporting period is 7,060, with 4,281 in production, 1,774 in technical roles, and 339 in sales[135][136].